IMPROVE-PD

IMPROVE PD is a European Action titled: ‘Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis’.

IMPROVE PD connects leading researchers who will collaborate in the shared goal of understanding the mechanisms of inflammation-driven cardiovascular disease in Peritoneal Dialysis (PD) patients, developing individualized approaches to identify those at risk, and testing new therapies in them.

Network-wide and local training activities including academies and satellite modules associated with large nephrology conferences, combined with individual research projects, intersectoral secondments and short laboratory visits, will provide key generic skills including valorisation, entrepreneurship and intellectual property management and will prepare ESRs for future roles as highly skilled research leaders in Europe.

FUNDING PROGRAMME

 

 

 

 

IMPROVE-PD is funded by the Horizon 2020 Framework Programme of the European Union through the Marie Skłodowska-Curie Programme as an Innovative Training Network (ITN-ETN).

The aim of this Programme is to train a new generation of creative, entrepreneurial and innovative early-stage researchers, able to face current and future challenges and to convert knowledge and ideas into products and services for economic and social benefit.

CALL FOR APPLICATIONS

IMPROVE-PD will offer 15 young scientists (Early Stage Researchers, ESRs) who will work in close partnership with 22 institutions located in 9 different countries in an excellent, multidisciplinary and intersectoral pan-European PhD-level training programme delivered by outstanding academic, clinical and industrial stakeholders.

An international call for applications will be published shortly in order to detail the procedure and requirements to become an IMPROVE-PD ESR.

CONSORTIUM

The IMPROVE PD consortium connects leading academic and industrial researchers in this field internationally, who will cooperate in the shared goal of understanding the mechanisms of inflammation-driven cardiovascular disease in PD patients, developing individualized approaches to identify those at risk, and testing new therapies in them.

CONSORTIUM MEMBERS

COORDINATOR

Agencia Estatal Consejo Superior de Investigaciones Científicas (ES)

BENEFICIARIES

PARTNER ORGANISATIONS

Cardiff University (UK)

Dutch Kidney Foundation (NL)

Baxter Healthcare (AT)

The European Peritoneal Dialysis Association (UK)

INSERM Nancy Clinical Investigation Centre (FR)

Fresenius Medical Care (DE)

University of Keele (UK)

Kidney Research UK (UK)

epsilon 3 (AT)

Medical University of Vienna (AT)

Université Catholique de Louvain (BE)

Servicio Madrileño de Salud- Instituto de Investigación del Hospital Universitario La Paz (ES)

Universitaets-Klinikum Heidelberg (DE)

University of Ghent (BE)

Stichting VU-VUMC (NL)

Renal Registry UK (UK)

Zytoprotec GmbH (AT)

Australia/New Zealand Renal Registry (AU)

Universidad Autónoma de Madrid (ES)

Poznan University of Medical Science (PL)

 

Institut de Recerca Biomèdica de Lleida (ES)